Webinar series - Current topics in Alzheimer's disease diagnostics

As a Neurologist of the Sant Pau Memory Unit, he has, during the last 10 years, gained clinical expertise in the diagnosis and treatment of patients with memory problems. His main research interests are the discovery and implementation of fluid biomarkers for the early and accurate diagnosis of neurodegenerative diseases. His studies have significantly contributed to this field and are reflected in numerous publications in high impact journals. He combines clinical research with academic responsibilities as a Clinical Associate in the Faculty of Medicine at the Autonomous University of Barcelona.

For more than 20 years he has been working on diagnostic and research aspects of cerebrospinal fluid, including a large panel of neurologic and psychiatric disorders, with a particular scope on neurodegenerating conditions, like Alzheimer’s disease. In 2004 he obtained the Certificate of Expertise from the German Society of Clinical Neurochemistry and currently he is a member of the Extended Board of the same society.

Responsible for the outpatient ward of the Memory Clinic at Skåne University Hospital and co-director of the strategic research area of neuroscience at Lund University. During the last 15 years, he has performed outstanding clinical and translational research that has been instrumental for the implementation of cerebrospinal fluid biomarkers in the clinical work-up of Alzheimer’s disease in Sweden and internationally. With the BioFINDER study, he focuses on the development of diagnostic algorithms for early diagnosis that include blood-based biomarkers.

She has wide experience in the field of neurodegenerative disease research, and her activity includes clinical characterization of patients with dementia and research on biomarker discovery and validation. Her main expertise is in the field of cerebrospinal fluid biomarkers for early diagnosis of neurodegenerative diseases, with special interest in Alzheimer’s disease and Parkinson’s disease.

Expert in the field of fluid biomarkers in inflammatory and degenerative diseases of the central nervous system, such as multiple sclerosis, Alzheimer’s disease, and Parkinson’s disease, with an interest on the potential pathophysiological implications of cerebrospinal fluid biomarkers research in these diseases. His research activity focuses on the potential clinical diagnostic and prognostic application of neuronal injury biomarkers as well as in the characterization of immunological markers both in autoimmune and degenerative neurological diseases.

Her drive is to improve care of patients with neurological diseases by developing body fluid biomarkers for diagnosis, stratification, prognosis and monitoring treatment responses. Studies of her research group span the entire spectrum of biomarker development, from biomarker identification to extensive clinical validation and implementation in clinical practice. She is responsible for the large well characterized biobank of the Amsterdam Dementia cohort, containing >5200 paired CSF and serum samples. She also leads several collaborative international biomarker networks.

Joined Innogenetics (today Fujirebio Europe) in 1996 and played a pioneering role in the development of the world’s first cerebrospinal fluid-based assays for biomarker detection as an aid in the diagnosis of Alzheimer’s disease. As product development manager, he continues to play an essential part in the development of new diagnostic pathways and partnerships for neurodegeneration diagnostics at Fujirebio today. He has participated in several international consortia and working groups aiming for a better and more standardized diagnosis of Alzheimer’s disease.